through the merger with Immunex a year later, of the anti-TNFmonoclonal antibody Enbrel. Amgen’s oncology portfolio achieved a number of successes too, with Kepivance being approved for oral ...

Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel.

In November 2000, Immunex (Seattle, WA ... the wings with new drugs for treating rheumatoid arthritis. These include Amgen's (Thousand Oaks, CA) Anakinra, an interleukin 1 antagonist expected ...